Equities Analysts Issue Forecasts for KYTX FY2027 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Kyverna Therapeutics in a report issued on Monday, March 30th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($2.67) per share for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company lifted their price target on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Morgan Stanley set a $33.00 price objective on Kyverna Therapeutics in a research note on Monday, December 15th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Price Performance

KYTX opened at $8.63 on Tuesday. The stock has a fifty day moving average of $8.26 and a 200-day moving average of $7.69. The firm has a market capitalization of $377.99 million, a P/E ratio of -2.36 and a beta of 3.32. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $13.67. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80).

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently modified their holdings of KYTX. Bank of America Corp DE boosted its position in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in Kyverna Therapeutics by 31.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after purchasing an additional 16,267 shares during the last quarter. AQR Capital Management LLC acquired a new position in Kyverna Therapeutics in the 1st quarter worth about $137,000. Rhumbline Advisers raised its stake in shares of Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Kyverna Therapeutics during the 2nd quarter worth about $107,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.